このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

急性心不全治療のためのケトンエステル (KETO-AHF)

2026年11月4日 更新者:University of Alberta

KETO-AHF: 急性心不全治療のためのケトンエステル: 先駆的無作為化比較試験

Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.

調査の概要

詳細な説明

KETO-AHF (Ketone Ester for Treatment of Acute Heart Failure) is a single-site, double-blind, randomized, placebo-controlled vanguard clinical trial evaluating the feasibility, safety, and preliminary efficacy of exogenous ketone ester therapy in adults hospitalized with acute heart failure (AHF). The trial is conducted as a domain within the Heart Failure Efficacy and Research Trial (HEART) Platform master protocol framework.

Adults (≥18 years) admitted with a primary diagnosis of acute heart failure will be screened and enrolled within 48 hours of hospital admission. Eligible participants must have dyspnea and clinical evidence of congestion and meet protocol-specified laboratory and clinical criteria, including elevated NT-proBNP and adequate kidney function (eGFR >15 mL/min/1.73m²). Key exclusions include type 1 diabetes mellitus, dialysis dependence, inability to tolerate enteral therapy, and need for advanced mechanical circulatory support or inopressor therapy.

Participants will be randomized 1:1 to receive ketone ester therapy or matching placebo for up to 5 consecutive days (or until hospital discharge or death), in addition to standard-of-care acute heart failure management. Randomization will occur through a centralized web-based system using stratified randomization by sex, and both participants and study staff will remain blinded to allocation.

The investigational intervention is KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol), administered orally or enterally at 25 g three times daily (total 75 g/day). The placebo arm receives a taste- and appearance-matched placebo administered on the same schedule. Study drug administration occurs after meals with flexibility to accommodate clinical care.

The primary endpoint is change in NT-proBNP over the treatment period. Secondary outcomes include change in heart failure symptoms using the Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score and change in echocardiographic measures of cardiac function. Exploratory outcomes include glycemic control and insulin requirements, renal function, daily fluid balance adjusted for diuretic dose, and clinical outcomes through 30 days including mortality and days alive and out of hospital. The vanguard design also evaluates feasibility outcomes to inform a subsequent full-scale trial, including consent rate, representation of women, intervention adherence, and follow-up completeness.

Safety monitoring includes daily clinical assessment and laboratory monitoring (including acid-base measures), with predefined adverse events of special interest and stopping rules. An independent Data Safety Monitoring Committee (DSMC) reviews safety data at prespecified enrollment intervals.

研究の種類

介入

入学 (推定)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Justin Ezekowitz, MD
  • 電話番号:780-492-0712
  • メール:jae2@ualberta.ca

研究連絡先のバックアップ

  • 名前:Fernando G Zampieri, MD, PhD
  • 電話番号:587-588-6151
  • メール:fzampier@ualberta.ca

研究場所

    • Alberta
      • Edmonton、Alberta、カナダ
        • University of Alberta

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Domain-Specific Inclusion Criteria:

  1. Primary diagnosis of AHF with dyspnea on exertion or at rest, and at least two of the following: congestion on chest radiograph, rales on chest auscultation, clinically relevant edema, or an elevated jugular venous pressure [21]
  2. Admitted to the hospital for less than 48 hours
  3. Estimated glomerular filtration rate above 15 mL/min/1.73m²
  4. NT-proBNP ≥ 1000 pg/ml

Domain-Specific Exclusion Criteria:

  1. Type 1 diabetes mellitus
  2. Patients on mechanical circulatory support
  3. Patients on more than one inotrope or on inopressors
  4. Patients on dialysis
  5. Patients with non-functioning enteral tracks

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:KetoneAid MonoEster

Intervention Name: KetoneAid MonoEster Formulation: D-Beta Hydroxybutyrate bonded to R 1,3 Butanediol Dosing: 25 grams, three times per day Administration: Oral or enteral route Duration: 5 consecutive days, or until hospital discharge or death

Participants randomized to the intervention arm will receive KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol) administered orally or enterally at a dose of 25 g three times daily (total 75 g/day) for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management.

プラセボコンパレーター:Placebo

Matching placebo, also provided by KetoneAid, with similar administration instructions.

Participants randomized to the control arm will receive a matching placebo administered orally or enterally three times daily for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in NT-proBNP
時間枠:Baseline to Day 5 (or hospital discharge if earlier)

Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) level over the 5-day intervention period comparing ketone ester versus placebo.

Baseline to Day 5 (or hospital discharge if earlier)

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)
時間枠:Baseline to Day 5 (or hospital discharge if earlier)

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score from baseline to Day 5 comparing treatment groups.

The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) ranges from 0 to 100, where higher scores indicate fewer heart failure symptoms and better health status, and lower scores indicate more severe symptoms and worse health status.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Left Ventricular Ejection Fraction (LVEF)
時間枠:Baseline to Day 5 (or hospital discharge if earlier)

Change in left ventricular ejection fraction from baseline to Day 5 comparing ketone ester versus placebo.

Left ventricular ejection fraction is expressed as a percentage (%), with higher values indicating better systolic function.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Mitral Inflow E/e' Ratio
時間枠:Baseline to Day 5 (or hospital discharge if earlier)

Change in mitral inflow E/e' ratio from baseline to Day 5 comparing ketone ester versus placebo.

E/e' ratio is a unitless measure of left ventricular filling pressure. Higher values indicate higher estimated filling pressures and worse diastolic function.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Stroke Volume
時間枠:Baseline to Day 5 (or hospital discharge if earlier)

Change in stroke volume from baseline to Day 5 comparing ketone ester versus placebo.

Stroke volume is measured in milliliters (mL). Higher values indicate greater forward blood flow per heartbeat.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Tricuspid Annular Plane Systolic Excursion (TAPSE)
時間枠:Baseline to Day 5 (or hospital discharge if earlier)

Change in tricuspid annular plane systolic excursion from baseline to Day 5 comparing ketone ester versus placebo.

TAPSE is measured in millimeters (mm). Higher values indicate better right ventricular systolic function.

Baseline to Day 5 (or hospital discharge if earlier)

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in serum creatinine
時間枠:Baseline to Day 5 (or discharge if earlier)

Change in renal function measured by serum creatinine over the intervention period.

Baseline to Day 5 (or discharge if earlier)
Insulin requirements
時間枠:Day 1 through Day 5 (or discharge if earlier)

Total insulin administered during the inpatient intervention period.

Day 1 through Day 5 (or discharge if earlier)
Glycemic control
時間枠:Day 1 through Day 5 (or discharge if earlier)

Daily blood glucose measurements during the intervention period.

Day 1 through Day 5 (or discharge if earlier)
Days Alive and Out of Hospital
時間枠:30 days

Number of days alive and out of hospital through Day 30 after randomization.

30 days
All-cause mortality
時間枠:30 days

All-cause mortality through Day 30 after randomization.

30 days
Major Adverse Kidney Events
時間枠:30 days

Composite kidney outcome through Day 30, including death, new renal replacement therapy, or persistent renal dysfunction.

30 days
Daily Net Fluid Balance Adjusted for Loop Diuretic Dose
時間枠:Day 1 through Day 5 (or hospital discharge if earlier)

Daily net fluid balance during the inpatient intervention period (Day 1 through Day 5 or hospital discharge if earlier), adjusted for total loop diuretic dose administered.

Net fluid balance will be calculated as total fluid intake minus total fluid output and normalized to loop diuretic dose received during the same period.

Day 1 through Day 5 (or hospital discharge if earlier)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Fernando G Zampieri, MD, PhD、University of Alberta

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2027年7月1日

研究の完了 (推定)

2028年3月1日

試験登録日

最初に提出

2026年1月15日

QC基準を満たした最初の提出物

2026年2月19日

最初の投稿 (実際)

2026年2月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • KETO-01

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する